JP4511924B2 - 置換チオフェン、その製造方法、医薬または診断薬としてのその使用、および、これを含有する医薬 - Google Patents

置換チオフェン、その製造方法、医薬または診断薬としてのその使用、および、これを含有する医薬 Download PDF

Info

Publication number
JP4511924B2
JP4511924B2 JP2004509675A JP2004509675A JP4511924B2 JP 4511924 B2 JP4511924 B2 JP 4511924B2 JP 2004509675 A JP2004509675 A JP 2004509675A JP 2004509675 A JP2004509675 A JP 2004509675A JP 4511924 B2 JP4511924 B2 JP 4511924B2
Authority
JP
Japan
Prior art keywords
hydrogen
methyl
chloro
benzimidazolylamino
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2004509675A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005533038A (ja
JP2005533038A5 (cg-RX-API-DMAC7.html
Inventor
ハンス−ヨッヘン・ラング
ウーヴェ・ハイネルト
アルミン・ホーフマイスター
クラウス・ヴィルト
ミヒャエル・ゲクレ
マルクス・ブライヒ
Original Assignee
サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング filed Critical サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング
Publication of JP2005533038A publication Critical patent/JP2005533038A/ja
Publication of JP2005533038A5 publication Critical patent/JP2005533038A5/ja
Application granted granted Critical
Publication of JP4511924B2 publication Critical patent/JP4511924B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2004509675A 2002-06-04 2003-05-26 置換チオフェン、その製造方法、医薬または診断薬としてのその使用、および、これを含有する医薬 Expired - Fee Related JP4511924B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10224892A DE10224892A1 (de) 2002-06-04 2002-06-04 Substituierte Thiophene, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
PCT/EP2003/005465 WO2003101984A1 (de) 2002-06-04 2003-05-26 Substituierte thiophene, verfahren zu ihrer herstellung, ihre verwendung als medikament oder diagnostikum sowie sie enthaltendes medikament

Publications (3)

Publication Number Publication Date
JP2005533038A JP2005533038A (ja) 2005-11-04
JP2005533038A5 JP2005533038A5 (cg-RX-API-DMAC7.html) 2006-06-22
JP4511924B2 true JP4511924B2 (ja) 2010-07-28

Family

ID=29557542

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004509675A Expired - Fee Related JP4511924B2 (ja) 2002-06-04 2003-05-26 置換チオフェン、その製造方法、医薬または診断薬としてのその使用、および、これを含有する医薬

Country Status (32)

Country Link
EP (1) EP1513834B1 (cg-RX-API-DMAC7.html)
JP (1) JP4511924B2 (cg-RX-API-DMAC7.html)
KR (1) KR101087966B1 (cg-RX-API-DMAC7.html)
CN (1) CN1324024C (cg-RX-API-DMAC7.html)
AR (1) AR040239A1 (cg-RX-API-DMAC7.html)
AT (1) ATE320425T1 (cg-RX-API-DMAC7.html)
AU (1) AU2003273553B2 (cg-RX-API-DMAC7.html)
BR (1) BR0311548A (cg-RX-API-DMAC7.html)
CA (1) CA2488242C (cg-RX-API-DMAC7.html)
CR (1) CR7577A (cg-RX-API-DMAC7.html)
DE (2) DE10224892A1 (cg-RX-API-DMAC7.html)
DK (1) DK1513834T3 (cg-RX-API-DMAC7.html)
EC (1) ECSP045471A (cg-RX-API-DMAC7.html)
ES (1) ES2258722T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20041153A2 (cg-RX-API-DMAC7.html)
IL (1) IL165519A (cg-RX-API-DMAC7.html)
MA (1) MA27204A1 (cg-RX-API-DMAC7.html)
ME (1) MEP27608A (cg-RX-API-DMAC7.html)
MX (1) MXPA04011986A (cg-RX-API-DMAC7.html)
MY (1) MY129832A (cg-RX-API-DMAC7.html)
NO (1) NO329351B1 (cg-RX-API-DMAC7.html)
OA (1) OA12827A (cg-RX-API-DMAC7.html)
PE (1) PE20040534A1 (cg-RX-API-DMAC7.html)
PL (1) PL372589A1 (cg-RX-API-DMAC7.html)
PT (1) PT1513834E (cg-RX-API-DMAC7.html)
RS (1) RS51141B (cg-RX-API-DMAC7.html)
RU (1) RU2315766C2 (cg-RX-API-DMAC7.html)
TN (1) TNSN04240A1 (cg-RX-API-DMAC7.html)
TW (1) TWI283675B (cg-RX-API-DMAC7.html)
UA (1) UA77551C2 (cg-RX-API-DMAC7.html)
WO (1) WO2003101984A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200409095B (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040242560A1 (en) 2003-05-22 2004-12-02 Aventis Pharma Deutschland Gmbh Process for synthesizing heterocyclic compounds
DE10323701A1 (de) 2003-05-22 2004-12-23 Aventis Pharma Deutschland Gmbh Verfahren zur Synthese heterocyclischer Verbindungen
EP1640361B9 (en) 2003-06-30 2015-11-04 Sumitomo Chemical Company, Limited Asymmetric urea compounds and process for producing asymmetric compounds by asymmetric conjugate addition reaction using the same as catalyst
JP2010507664A (ja) * 2006-10-25 2010-03-11 武田薬品工業株式会社 ベンズイミダゾール化合物
EP2342178B1 (en) 2008-09-02 2016-09-28 Sanofi Substituted aminoindanes and analogs thereof, and the pharmaceutical use thereof
RU2373929C1 (ru) * 2008-11-11 2009-11-27 Государственное образовательное учреждение высшего профессионального образования "БАШКИРСКИЙ ГОСУДАРСТВЕННЫЙ МЕДИЦИНСКИЙ УНИВЕРСИТЕТ Федерального Агентства по здравоохранению и социальному развитию" (ГОУ ВПО БГМУ РОСЗДРАВА) Корректор системы гемостаза, проявляющий ингибирующее действие на адгезивно-агрегационную функцию тромбоцитов для профилактики патологического тромбообразования
WO2011058139A1 (en) * 2009-11-12 2011-05-19 Selvita Sp. Z O. O. A compound, a process for its preparation, a pharmaceutical composition, use of a compound, a method for modulating or regulating serine/threonine kinases and a serine/threonine kinases modulating agent
RU2518740C1 (ru) * 2013-03-22 2014-06-10 Федеральное государственное автономное образовательное учреждение высшего профессионального образования "ЮЖНЫЙ ФЕДЕРАЛЬНЫЙ УНИВЕРСИТЕТ" СРЕДСТВО, ИНГИБИРУЮЩЕЕ Na+/H+-ОБМЕН, И ДИГИДРОХЛОРИД 2-(3,4-МЕТИЛЕНДИОКСИФЕНИЛ)-9-МОРФОЛИНОЭТИЛИМИДАЗО[1,2-a]БЕНЗИМИДАЗОЛА
WO2016013657A1 (ja) 2014-07-25 2016-01-28 大正製薬株式会社 ヘテロアリールで置換されたフェニルテトラヒドロイソキノリン化合物
KR102840252B1 (ko) * 2023-04-27 2025-07-30 한국화학연구원 시아노벤즈이미다졸 유도체, 약제학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 약제학적 조성물
CN120112529B (zh) * 2023-09-28 2026-01-06 四川大学华西医院 一种含吡啶的化合物及其制备方法和用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE754820R (fr) * 1969-08-13 1971-02-15 Schering Ag Nouveaux derives de pyrimidine, leurs procedes de preparation et leurs
BR6915362D0 (pt) * 1969-08-16 1973-01-04 Hoechst Ag Processo para a preparacao de 2(tienil-3-amino)1,3-diazacicloalquenos
DE2830279A1 (de) * 1978-07-10 1980-01-31 Boehringer Sohn Ingelheim 2-eckige klammer auf n-(2'-chlor-4'- methyl-thienyl-3')-n-(cyclopropylmethyl)- amino eckige klammer zu-imidazolin-(2), dessen saeureadditionssalze, dieses enthaltende arzneimittel und verfahren zu seiner herstellung
US5395847A (en) * 1993-12-02 1995-03-07 Smithkline Beecham Corporation Imidazolyl-alkenoic acids
WO2000006169A1 (en) * 1998-07-29 2000-02-10 Merck & Co., Inc. Integrin receptor antagonists
DE19921883A1 (de) * 1999-05-12 2000-11-16 Bayer Ag Substituierte Thienocycloalk(en)ylamino-1,3,5-triazine
DE19960204A1 (de) * 1999-12-14 2001-06-28 Aventis Pharma Gmbh Substituierte Norlbornylamino-Derivate, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
MXPA04009541A (es) * 2002-03-29 2005-01-25 Chiron Corp Benzazoles sustituidos y uso de los mismos como inhibidores de cinasa raf.

Also Published As

Publication number Publication date
RS103804A (sr) 2006-12-15
DK1513834T3 (da) 2006-07-17
ES2258722T3 (es) 2006-09-01
PL372589A1 (en) 2005-07-25
RU2315766C2 (ru) 2008-01-27
KR101087966B1 (ko) 2011-12-01
KR20050005532A (ko) 2005-01-13
IL165519A (en) 2010-05-31
BR0311548A (pt) 2005-04-12
DE50302673D1 (de) 2006-05-11
RU2004138812A (ru) 2005-07-20
EP1513834A1 (de) 2005-03-16
MEP27608A (en) 2010-06-10
CA2488242C (en) 2011-08-02
CN1324024C (zh) 2007-07-04
CN1659163A (zh) 2005-08-24
OA12827A (en) 2006-07-11
IL165519A0 (en) 2006-01-15
MXPA04011986A (es) 2005-03-07
RS51141B (sr) 2010-10-31
WO2003101984A1 (de) 2003-12-11
JP2005533038A (ja) 2005-11-04
AR040239A1 (es) 2005-03-23
HK1076460A1 (en) 2006-01-20
PE20040534A1 (es) 2004-10-25
CR7577A (es) 2005-06-16
NO329351B1 (no) 2010-10-04
ZA200409095B (en) 2005-05-10
ECSP045471A (es) 2005-01-28
MA27204A1 (fr) 2005-01-03
CA2488242A1 (en) 2003-12-11
NO20045504L (no) 2005-01-25
EP1513834B1 (de) 2006-03-15
AU2003273553B2 (en) 2008-12-04
UA77551C2 (en) 2006-12-15
TW200406409A (en) 2004-05-01
MY129832A (en) 2007-05-31
PT1513834E (pt) 2006-06-30
DE10224892A1 (de) 2003-12-18
TNSN04240A1 (en) 2007-03-12
HRP20041153A2 (en) 2005-06-30
ATE320425T1 (de) 2006-04-15
TWI283675B (en) 2007-07-11
AU2003273553A1 (en) 2003-12-19

Similar Documents

Publication Publication Date Title
US7488746B2 (en) Substituted thiophenes: compositions, processes of making, and uses in disease treatment and diagnosis
JP4323803B2 (ja) 置換2−アニリノーベンゾイミダゾール及びnhe阻害剤としてのその使用
EP1794128B1 (de) Substituierte 4-phenyltetrahydroisochinoline, verfahren zu ihrer herstellung, ihre verwendung als medikament, sowie sie enthaltendes medikament
JP2005533038A (ja) 置換チオフェン、その製造方法、医薬または診断薬としてのその使用、および、これを含有する医薬
JP2008526906A (ja) 置換4−フェニルテトラヒドロイソキノリン、それらの製造方法、薬物としてのそれらの使用およびそれらを含む薬物
JP5249918B2 (ja) 置換された1−アミノ−4−フェニル−ジヒドロイソキノリン、それらの製造法、それらの薬剤としての使用、およびそれらを含有する薬剤
US7179830B2 (en) Substituted thienoimidazoles useful for disease treatment and prevention
JP4630270B2 (ja) N−置換(ベンゾイミダゾール−2−イル)フェニルアミン、それらの製造方法、医薬又は診断剤としてのそれらの使用及び該物質を含有する医薬
NZ536970A (en) Substituted thiophenes, method for the production thereof, their use as a medicament or diagnostic reagent, and a medicament containing the same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060502

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060502

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100315

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20100315

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100413

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100507

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130514

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130514

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees